hVIVO Projects £55-60M Revenue in Analyst Day Slides

hVIVO published its analyst and investor day slide deck Friday, detailing a growth strategy built on its human challenge trial platform. The presentation covers the company's controlled human infection studies, where volunteers are exposed to respiratory pathogens in a quarantined setting to test vaccine and treatment candidates.

The deck shows a booked order book of roughly £100 million, with revenue projected at £55-60 million for 2026, up from £32 million in 2023. Management cited gross margins in the 40-45% range and argued that model standardization will push those higher over time. The company carries no debt and generates positive free cash flow, a point the slides frame as a structural advantage in a capital-intensive industry.

Capacity expansion is a central theme. hVIVO runs its London quarantine facility and plans to add about 30% more bed space over the next 18 months, funded from operating cash flow. The buildout is tied to growing demand from drug developers and regulators for faster efficacy data through challenge trials.

The slides estimate the global challenge trial market at £300-500 million. hVIVO's current share is roughly 15-20%, leaving room for growth. The order book provides visibility into 2027, with repeat contracts from large pharma and biotech clients increasingly replacing one-off trial revenue.

hVIVO is scheduled to report interim results in September.